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Objective: To evaluated the relationship between the genetic variations at IL-8 +2767
position with VL pathogenesis among Iranian patients.
Methods: Three groups including patients with VL clinical presentation and leishmania
seropositive (n = 124), patients seropositive but without clinical presentation (n = 82) and
healthy controls (n = 63) were selected to conduct this cross-sectional study. Poly-
morphism at +2767 position of IL-8 was investigated using PCR-RFLP techniques. Anti-
leishmania antibody titration was evaluated by the immunoﬂorescence technique.
Results: We observed higher signiﬁcant frequencies +2767 A/A and A/T genotypes in
Group 1 compared to Group 2 and healthy controls (P = 0.001). Also, patients in Group 1
carrying A/A genotype showed higher titer of anti-leishmania antibody than patients with
A/T and T/T genotypes (P = 0.05). The validity of the data was analyzed using Hardy–
Weinberg equilibrium and one way analysis of variance (ANOVA), as well as c2 tests.
Conclusions: Our ﬁndings indicate that the IL-8 +2767 polymorphism is signiﬁcantly
involved in impaired immune responses against VL and it could be considered as a risk
factor for the VL progress.1. Introduction
Leishmaniasis, a serious public health problem, is a proto-
zoan disease with multiple clinical features which manifests
predominantly in cutaneous, diffuse cutaneous, mucocutaneous
and visceral clinical forms [1]. Visceral Leishmaniasis (VL)
infections or Kala Azar result in the most severe forms of the
disease [2], causing death if left untreated, and are endemic in
tropical and sub-tropical regions [3]. It can be undiagnosed or
develop into clinical manifestations, including fever, weight
loss, pancytopenia, febrile splenomegaly and hepatomegaly [4].
Although VL infection is a protozoan disease, immunologic
dysfunctions play a vital role in VL pathogenesis. A mainaspect of the disease is a deﬁcit in immune response to
leishmania antigen and lymphokine production [5,6].
Interleukin 8 (IL-8), a proinﬂammatory cytokine, is produced
by leukocytes as well as many types of tissues upon inﬂam-
matory conditions and neutrophils are considered to be major
speciﬁc targets for IL-8 action [7]. Therefore, genetic variations
in IL-8 gene resulting in IL-8 expression levels may affect im-
mune responses and leishmaniasis phenotype [8]. It has been
implicated that the functional polymorphism at +2767
(rs1126647) position located within 30UTR of IL-8 gene may
inﬂuence the level of IL-8 expression [9]. This study aimed to
evaluate whether the progress of VL can be associated with
IL-8 +2767 polymorphism in the seropositive VL patients
with and without clinical presentation.
2. Materials and methods
This cross-sectional research was carried out on 124 VL sero-
positive patients with clinical presentation (Group 1), 82 sero-
positive patients without clinical presentation (Group 2) and 63
healthy controls (Group 3) to evaluate IL-8 +2767 A/T poly-
morphism. An expert infectious diseases specialist diagnosed VL
in participants based on medical history, clinical presentations and
laboratoryﬁndings [10]. TheVLpatients and participants inGroupsrticle under the CC BY-NC-ND license (http://
Table 2
Anti-leishmania antibody titration in Groups 1 and 2 with various IL-
8 +2767 A/T polymorphism.
Polymorphism Group 1 Group 2
IL-8 +2767 A/A genotype 3.20 ± 0.32 3.50 ± 0.18
IL-8 +2767 A/T genotype 3.00 ± 0.20 3.80 ± 0.13
IL-8 +2767 T/T genotype 2.40 ± 0.24 3.70 ± 0.12
P value 0.053 0.310
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is endemic [11]. The participants ﬁlled out an informed consent
form and the ethical approval for this study was obtained from
Hamadan University of Medical Sciences.
2.1. DNA extraction and polymorphism detection
Genomic DNA was extracted from peripheral blood using a
commercial kit (Bioneer, South Korea) based on the manufac-
turer's instructions.
The IL-8 +2767 A/T gene polymorphism was evaluated us-
ing RFLP techniques.
To amplify the regions containing this site, PCR was per-
formed in a ﬁnal volume of 20 mL containing 1.5 mM MgCl2,
0.2 mM of each dNTP [(dATP, dCTP, dGTP, dTTP), 10 pM of
each primer (25 ng/mL), 0.5 of Taq DNA polymerase, 100 ng of
prepared DNA template and 1× PCR buffer. The forward and
reverse primers sequencing for ampliﬁcation of the IL-8 +2767
A/T (222 bp) containing position are F: 50-CCAGT-
TAAATTTTCATTTCAGGTA-30; R: 50-CAACCAGCAA-
GAAATTACTAA-30. The PCR condition was as follows: 1
cycle of 95 C for 5 min (denaturation) then 35 cycles of 30 s at
95 C, 53 C for 30 s and 72 C for 40 s using a thermal cycler
(Bioneer, South Korea). The PCR product was digested with
BstZ17I (Fermentase Company, Finland) in the case of T allele
into 198 bp and 24 bp sub-fragments. Thereafter, the PCR
product was separated on an ethidium bromide pretreated 2.5%
agarose gel in parallel with a 50 bp ladder (Cinnaclon, Iran).
2.2. Immunoﬂorescence assay
Anti-leishmania antibody titration was performed with a
commercial kit from Qiagen Company, USA, based on the
manufacturer's instructions.
2.3. Statistical analysis
The validity of data was evaluated using Hardy–Weinberg
equilibrium and the One Way ANOVA as well as c2 tests were
used to determine the differences between groups by using the
SPSS software version 13. A P value less than 0.05 was
considered as signiﬁcant.
3. Results
The results from polymorphism analysis showed that the
polymorphism at +2767 (P = 0.001) was signiﬁcantly associated
with VL. We found that +2767 A/A genotype signiﬁcantly
increased in Group 1 compared to Groups 2 and 3 (Table 1). TheTable 1
The status of IL-8 +2767 A/T polymorphism in patients with clinical
presentation of VL and seropositive for the leishmania (Group 1), without
clinical presentation but seropositive (Group 2) and healthy controls
(Group 3).
Polymorphism Group 1 Group 2 Group 3
P
value
IL-8 +2767
A/T
polymorphism
Geno-
types
A/A 25 (20.1) 18 (17.6) 3 (4.8) 0.001
A/T 55 (44.4) 44 (43.1) 19 (30.2)
T/T 44 (35.5) 40 (39.2) 41 (65.0)
Alleles A 105 (42.3) 80 (39.2) 25 (19.8) 0.001
T 143 (57.7) 124 (60.8) 101 (80.2)statistical analysis demonstrated a signiﬁcant difference between
groups regarding +2767A and T alleles (P< 0.001, Table 1). Anti-
leishmania antibody levels amongVLpatients with the +2767A/A
genotype was higher than A/T and T/T genotypes (P = 0.05,
Table 2). As shown in Table 2, the anti-leishmania antibody
titration among participants in Group 2 with various genotypes
within IL-8 +2767 positions was not statistically different.
4. Discussion
Our investigation provides the ﬁrst evidence that genetic
polymorphisms in IL-8 +2767 position among an Iranian pop-
ulation may be involved in impaired immune responses against
visceral leishmaniasis. Since IL-8 plays a crucial role in the
induction of immune responses against leishmaniasis, genetic
variations that inﬂuence IL-8 expression or function may
contribute to clinically observed leishmaniasis phenotypes and
impaired immune response [12]. T cell-mediated immune
response predominantly plays signiﬁcant roles in human leish-
maniasis through secretion of cytokines including IL-4 and IL-
10, which induce Th1 and Th2 differentiation or IL-12, which
promotes Th1 development [12,13]. These observations prompted
us to investigate the clinical relevance between IL-8 genetic
variation +2767 position and leishmaniasis progress. We found
that genotypes and alleles within IL-8 +2767 position might be
involved in the VL development in Iranian population. In
addition, our results depicted that the IL-8 +2767 A/A genotype
was signiﬁcantly raised in Group 1 compared with Groups 2 and
3 (Table 2). Therefore, it is suggested that this genotype may be
associated with VL pathogenesis in Iranian populations. Our
hypothesis was veriﬁed by several studies focusing on IL-8
relationship with induction of immune responses against leish-
mania [8,14]. Additionally, it has been shown that contact with
Leishmania major results in IL-8 release by monocytes and
functions as a neutrophil chemotactic factor [15,16]. It has been
reported that Keratinocyte-derived cytokine (also known as
CXCL1), the functional murine homologues of human IL-8, is
rapidly produced in the skin during L. major infection [17]. On
the other hand, Kumar et al. found that IL-8 expression levels
were high in cutaneous leishmaniasis patients' sera [15].
Since +2767 A/A genotype is associated with VL, it is
suggested that this genotype may be involved up-regulation of
IL-8 in VL patients and further studies using luciferase assays
can be helpful to clarify this issue.
Finally, introducing this IL-8 genetic variation will help us to
understand the nature of VL and to design novel chemotherapies
or vaccine-based therapies which requires further studies on
immune modulations in VL patients [3].
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